X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

WHO Body Recommends Vaccines To Be Updated For Variants

Content Team by Content Team
13th January 2022
in News
The UK begins the biggest ever immunization program

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The technical body of the World Health Organization has confirmed that the COVID-19 vaccines, which the world is using currently, may have to be reworked to ensure their effectiveness against not only Omicron but future variants as well that may arise from nowhere. The technical group which is made up of independent experts, has confirmed that they would prefer a composition change in the vaccines to fight out the variants that are in line. All in all the current dosage of the range of brands of vaccinations that are being used for fighting out Coronavirus infection, according to these experts, must undergo an overhaul.

The technical body, in a statement issued from their end, has said that the vaccine composition may as well have to be updated in order to ensure that they continue to consistently provide the WHO-recommended levels of high protection against the infection as well as variants of concern that include delta, omicron, and other future variants.

The statement added that these vaccinations need to give out long-lasting responses, are strong and wide so as to eradicate the possibility of booster doses. The experts are of an opinion that the strategy based on repeat vaccination or booster, as we call them, may not be as suitable and sustainable as it looks.

That said, the statement hasn’t spilled any beans on advocacy of Omicron-specific vaccines, at least at this stage, and throws light on more research and data sharing. As per the statement, an updated vaccine specifically made to keep a check on dominant variants all at once must be the need of the hour.

As per the reports, the makers are already in the process of developing the generation next vaccines for Omicron and alike variants which are highly contagious. Albert Bourla, Chief Executive of Pfizer, has opined that a redesigned vaccination that focuses on Omicron in all likelihood will be needed, and their company may have one furnished by March. Moderna, on the other hand, is already working on a vaccine candidate, but that will not be available before two months. WHO has time and again said that the composition of vaccines will require global coordination, and it will be unfair to let the manufacturers decide alone and take the burden.

Previous Post

To Scale Up Quantum Drug Discovery, Oxford Joins Consortium

Next Post

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Cystic Fibrosis Treatment for 6-11 Years Old Gets A Nod

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In